宫内铂类化疗暴露后儿童听力损失发生率
因顺铂耳毒性顾虑,指南建议妊娠期优先选用卡铂,并推荐铂类暴露新生儿行听觉脑干反应检测。
要点
- 宫内铂类暴露儿童听力损失风险显著高于非铂类暴露者。
- 听力损失仅见于顺铂或卡铂暴露者,奥沙利铂暴露者未见。
- 铂类暴露新生儿推荐行听觉脑干反应检测,不论初筛结果。
核心结论
- 注册队列中仅宫内暴露于顺铂或卡铂的儿童被诊断听力损失。
- 奥沙利铂或非铂类暴露儿童未见听力损失。
- 因顺铂耳毒性顾虑,妊娠期可优先选用卡铂。
- 铂类暴露新生儿推荐行听觉脑干反应检测。
研究设计与样本
- 所有儿童接受新生儿耳声发射初筛,未通过者由听力学家评估。
- 比较铂类暴露伴与不伴听力损失儿童的产前产后治疗细节。
主要发现
- 4名儿童诊断听力损失,均暴露于铂类。
- 铂类暴露者听力损失4/43,非铂类暴露者0/264,p=0.0003。
- 39名铂类暴露无听力损失者中,奥沙利铂11名、顺铂16名、卡铂12名。
- 两组产前产后治疗细节无统计学差异。
关键数值与推荐
- 听力损失比较:铂类4/43 vs 非铂类0/264,p=0.0003。
- 4例听力损失者化疗方案:顺铂/紫杉醇2例,依托泊苷/顺铂/博来霉素1例,卡铂/紫杉醇1例。
- 原发癌:卵巢癌2例,宫颈癌2例。
临床怎么用
- 妊娠期需铂类化疗时,若等效母体生存,优先选用卡铂。
- 铂类宫内暴露新生儿应行听觉脑干反应检测,不论耳声发射初筛结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: When treated for childhood cancers, at least 50% of children exposed to platinum agents have permanent hearing loss. We determined the relative risk of childhood hearing loss after in utero exposure to platinum chemotherapy in our registry cohort. METHOD: After exposure to platinum chemotherapy in utero, all children undergo routine newborn hearing screening. This consists of Otoacoustic Emissions. Children who failed this screen were evaluated by audiologists. For those children with hearing loss by Automated Auditory Brainstem Response, prenatal and postnatal treatment details were compared to platinum exposed children without hearing loss. RESULTS: Three hundred and seven children were exposed to chemotherapy in utero. Four children were diagnosed with hearing loss, all exposed to platinum agents. Chemotherapy exposures included: Cisplatin/Paclitaxel (2), Etoposide/Cisplatin/Bleomycin (1), Carboplatin/Paclitaxel (1) to treat ovarian (2), or cervical cancer (2). Of the 39 platinum exposed without hearing loss: 11 children were exposed to oxaliplatin, 16 were exposed to cisplatin and 12 to carboplatin in utero. Two hundred and sixty four women received non-platinum based chemotherapy for various cancers during pregnancy. Among these, there were no cases of hearing loss. There was a significant difference in hearing loss based on exposure to platinum agents in utero compared to non-platinum-containing chemotherapy regimens, 4/43 versus 0/264, p = 0.0003. There were no statistical differences in prenatal and postnatal treatment details, including: gestational age at diagnosis, at first chemotherapy treatment, at first platinum treatment, at delivery (<32 weeks, <35 weeks, <37 weeks), gender, birthweight, birthweight percentile, rates of intrauterine growth restriction, neonatal complications or use of postnatal antibiotics between the platinum exposed children with and without hearing loss. CONCLUSION: The only children in the registry exposed to chemotherapy who were diagnosed with hearing loss had been exposed to cisplatin or carboplatin in utero. No hearing loss occurred in children exposed to oxaliplatin, or non-platinum agents. Due to a concern for cisplatin ototoxicity, carboplatin is the preferred platinum agent for use in pregnancy when equivalent maternal survival can be expected for the particular cancer type. For newborns exposed to platinum agents in utero, newborn screening with an auditory emissions test at birth (OES) may not detect sensorineural hearing loss and auditory brainstem response testing is recommended, regardless of the newborn screening result.
引用
- Finch LE, Cardonick EH. Incidence of childhood hearing loss after in utero exposure to platinum agents. Prenat Diagn. 2021. PMID: 34462927. doi:10.1002/pd.6035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。